BOCH
LRMR icon

Blue Owl Capital Holdings’s Larimar Therapeutics LRMR Stock Holding History

Blue Owl Capital Holdings’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Buy
9,163,157
+2,043,150
+29% +$8.11M 4.21% 4
2026
Q1 		$32M Buy
7,120,007
+296,317
+4% +$1.18M 8.61% 2
2025
Q4 		$26M Buy
6,823,690
+970,650
+17% +$3.78M 8.02% 4
2025
Q3 		$18.9M Buy
5,853,040
+925,000
+19% +$3.47M 5.87% 4
2025
Q2 		$14.2M Buy
4,928,040
+150,000
+3% +$347K 4.6% 6
2025
Q1 		$10.3M Buy
4,778,040
+125,000
+3% +$395K 3.31% 9
2024
Q4 		$18M Buy
4,653,040
+486,211
+12% +$3.21M 4.15% 10
2024
Q3 		$27.3M Buy
4,166,829
+307,361
+8% +$2.47M 5.26% 7
2024
Q2 		$28M Sell
3,859,468
-135,000
-3% -$1.03M 7.78% 5
2024
Q1 		$30.3M Buy
3,994,468
+580,000
+17% +$4.52M 6.06% 8
2023
Q4 		$15.5M Buy
+3,414,468
New +$11.5M 3.71% 9

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Blue Owl Capital Holdings's LRMR Position: Q2 2026 in Review

Blue Owl Capital Holdings increased its Larimar Therapeutics (LRMR) stake by 29% in Q2 2026, buying an estimated $8.11M and bringing the position to 9,163,157 shares worth $27.9M. The position accounts for 4.21% of the portfolio, ranked #4.

Blue Owl Capital Holdings first reported a position in LRMR in Q4 2023 and has held it in 11 quarters since. The position peaked at $32M in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Blue Owl Capital Holdings held 9,163,157 shares of Larimar Therapeutics worth $27.9M as of Q2 2026.
  • Blue Owl Capital Holdings bought 2,043,150 Larimar Therapeutics shares in Q2 2026, an estimated $8.11M.
  • Larimar Therapeutics made up 4.21% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #4 holding.
  • Blue Owl Capital Holdings first reported a position in Larimar Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Blue Owl Capital Holdings's Larimar Therapeutics position peaked at $32M in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.